MedDataX Logo

Does Mirabegron Have a Positive Impact on Sexual Function in Females With Overactive Bladder

NCT ID: NCT04511273

Last Updated: 2020-08-13

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

80 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-09-01

Study Completion Date

2021-04-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

80 female patients evaluated for sexual function after receiving Mirabegron 50 mg once daily for 6 months for treatment of overactive bladder symptoms

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Pharmacologic Effect for Female Overactive Bladder Syndrome: Mirabegron Versus Solifenacin

NCT04023253

Overactive Bladder Syndrome
UNKNOWN PHASE3

Mirabegron for Female OAB Patients: Comparison of Daytime and Nighttime Dosing

NCT03251300

Overactive Bladder Syndrome
UNKNOWN PHASE4

Therapeutic Efficacy and Safety of Mirabegron Treatment on Patients With Overactive Bladder Syndrome in Taiwan

NCT03044912

Overactive Bladder Syndrome
UNKNOWN PHASE3

Mirabegron Treatment on Patients With Overactive Bladder Syndrome in Taiwan

NCT03059134

Urinary Incontinence Overactive Bladder Syndrome
COMPLETED PHASE3

Efficacy and Safety of the Mirabegron Compared With Solifenacin in Treatment of Overactive Bladder

NCT03558919

Overactive Bladder
COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

80 female patients evaluated for sexual function after receiving Mirabegron 50 mg once daily for 6 months for treatment of overactive bladder symptoms

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Females With Overactive Bladder Symptoms, Urgency & Urge Incontinence

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Follow up of female sexual function

Mirabegron 50mg once daily for treatment of overactive bladder symptoms

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* any female with overactive bladder symptoms, urgency and urgency incontinence

Exclusion Criteria

* neurologic abnormalities
* Weak bladder contractility
* Diabetics
Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Kasr El Aini Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Samer Morsy

Urology Consultant

Responsibility Role PRINCIPAL_INVESTIGATOR

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Samer Morsy

Role: CONTACT

[email protected]
01000908851

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Cairo University Hospitals

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Mirabegron Combined With Behavioral Intervention for Overactive Bladder：a Prospective Multicenter Randomized Controlled Clinical Study
NCT05452434 UNKNOWN PHASE4
Effect of beta3-adrenoceptor Agonist on Patients With Overactive Bladder and as a Urinary Biomarker
NCT04693897 UNKNOWN
Mirabegron for the Treatment of Pain Motivated Urinary Frequency and Urgency in Women
NCT02981459 WITHDRAWN PHASE4
Comparative Study Between Behavior Therapy and Behavior Therapy Plus Mirabegron in Sexually Active Men With OAB Symptoms
NCT04420533 COMPLETED NA
Mirabegron and Urinary Urgency Incontinence
NCT02495389 COMPLETED PHASE4
A Prospective, Observational, Multicenter Study of Patients Following Initiation of a New Course of Treatment for Overactive Bladder (OAB)
NCT02386072 COMPLETED
Predictors for Retreatement of OAB After DC Mirabegron
NCT04550702 COMPLETED
A Study With Mirabegron 50 mg and 25 mg in Chinese Participants With Overactive Bladder
NCT04562090 COMPLETED PHASE4
Predictors Affecting Long-term Use of Solifenacin or Mirabegron in Women With Overactive Bladder Syndrome
NCT05040984 UNKNOWN
MIrabegron With oveRACtive bLadder Symptoms in mEn
NCT02361502 UNKNOWN PHASE4
Impact of Beta-3 Agonist on Psychological Distress and Blood Flow of the Bladder in Women With Overactive Bladder Syndrome
NCT03695822 WITHDRAWN PHASE4
Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Older Adult Subjects With Overactive Bladder (OAB)
NCT02216214 COMPLETED PHASE4
Management of OAB in Female Patients .
NCT06184334 COMPLETED NA
Prospective Study for Patient Perception of Treatment Satisfaction After Switching to Mirabegron in Patients With Overactive Bladder Who Were Unsatisfied With Efficacy of Antimuscarinic Therapy or Adverse Event.
NCT02468375 COMPLETED PHASE4
A Study to Evaluate the Efficacy and Safety of Mirabegron Compared to Solifenacin in Patients With Overactive Bladder Who Were Previously Treated With Another Medicine But Were Not Satisfied With That Treatment.
NCT01638000 COMPLETED PHASE3
Sequencing and Combination of Mirabegron and TTNS in Overactive Bladder Syndrome: a Multicenter, Randomized, Open-label, Crossover Trial
NCT05188742 UNKNOWN PHASE4
Comparisons of the Effects of Solifenacin Versus Mirabegron on Autonomic System, Arterial Stiffness and Psychosomatic Distress and Clinical Outcomes
NCT02540707 COMPLETED PHASE4
Comparisons of the Impact of Monotherapy With Mirabegron or Tolterodine Versus Combined Treatment With Mirabegron and Tolterodine on Autonomic Function and Bladder Blow Flow in Women With Overactive Bladder Syndrome: a Randomized Controlled Study
NCT05946902 UNKNOWN PHASE4
A Study to Evaluate the Effect of Mirabegron + Solifenacin in Overactive Bladder Patients
NCT01745094 COMPLETED PHASE4
A Trial Evaluating the Clinical Efficacy and Safety of Hibero SR (Mirabegron) 50 mg and Ditropan (Oxybutynin Chloride) 10 mg in Children Between 5 and 18 Years With Overactive Bladder (OAB)
NCT06181591 NOT_YET_RECRUITING PHASE2
Post-treatment Novmalized Urodynamiz Findings as the Golden Standard of Objective Cure for Female Overactive Bladder Patients Receiving Antimuscarinic Drug
NCT01627145 UNKNOWN NA
The Effect of Nighttime Mirabegron, Solifenacin, Tolterodine, or Oxybutynin on Nocturia, Sexual Function, Autonomic Function, and Lower Urinary Tract Blood Flow Perfusion in Women With Overactive Bladder Syndrome: Randomized Controlled Trial
NCT07114640 NOT_YET_RECRUITING PHASE3
Effectiveness of a Structured Intervention to Optimize the Use of Mirabegron
NCT03536494 COMPLETED NA
A Study to Test the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder
NCT00912964 COMPLETED PHASE3
Prevalence And Risk Factors of Overactive Bladder Syndrome Among Egyptian Medical Students, and Their Impact On Health-Related Quality Of Life
NCT07044778 COMPLETED